Gilead abandons phase 3 study of magrolimab for myelodysplastic syndromes
Source link
Gilead abandons phase 3 study of magrolimab for myelodysplastic syndromes
Previous ArticleStruggles at 0.8700, prints two-month high as ECB meeting looms

